Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Innovation is Scopus-indexed (Q1, CiteScore 4.4), WoS ESCI, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2770-9183Verify ISSN ↗2770-9191Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 11 / 57 | 81st | Q1 |
| Pharmacology (medical) | 119 / 278 | 57th | Q2 |
| Oncology | 192 / 428 | 55th | Q2 |
| Drug Discovery | 90 / 161 | 44th | Q3 |
| Cancer Research | 148 / 233 | 36th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q1, CiteScore 4.4.
Cancer Innovation is Q1 in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (rank 11 of 57), Q2 in Pharmacology (medical) (rank 119 of 278) and Q2 in Oncology (rank 192 of 428), by CiteScore 2025. It is ranked in 5 subject areas in all.
Cancer Innovation is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.4, which places it in quartile Q1 at the 81st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.921, quartile Q1, with an H-index of 13.
The publisher lists an article processing charge of about US$2,700 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Innovation is published by John Wiley and Sons Inc. Its print ISSN is 2770-9183 and its online ISSN is 2770-9191.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Innovation has an h-index of 18 and a 2-year mean of 3.73 citations per paper (OpenAlex). Its Scopus CiteScore is 4.4, quartile Q1. On 2-year citations it ranks #12 of 52 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (miscellaneous).
Cancer Innovation published 59 papers in 2025; its busiest recent year was 2023 with 68. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2024–2026), authors are most often from China (74.9%), United States (6.9%) and Japan (2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.